August 14, 2026

FDA approves tau PET imaging agent

The F18-labeled agent is indicated for brain PET imaging to identify tau neurofibrillary tangle pathology.

MDSpire News

August 12, 2026

FDA Clears Exoskeleton for Spinal Cord Injury

Use is limited to level indoor and adjoining outdoor areas and requires supervision by a companion with specialized training.

MDSpire News

August 11, 2026

DOJ Adds to Eye Fraud Settlements

Federal prosecutors allege two ophthalmology practices submitted false claims to Medicare and Medicaid for medically unnecessary transcranial Doppler ultrasounds.

MDSpire News

August 11, 2026

Midlife Vascular Risk Tied to Dementia-Free Survival

Patients with diabetes, hypertension, and current smoking in midlife lived nearly 13 fewer years without dementia than those with no vascular risk factors in a long-term US cohort study.

MDSpire News

August 04, 2026

PM2.5 Exposure May Be Linked to Lewy Dementias

Danish registry study found stronger associations for Lewy body dementia than Parkinson's disease–related dementia.

MDSpire News

July 31, 2026

Can SGLT2 Inhibitors Affect Dementia?

A target trial emulation using Veterans Affairs electronic health records examined neuropsychiatric outcomes associated with SGLT2 inhibitor use.

MDSpire News

July 31, 2026

Psilocybin Therapy May Ease Severe PTSD

Open‐label pilot trial found substantial symptom improvement and favorable safety findings in veterans receiving psilocybin-based therapy, supporting larger controlled studies.

MDSpire News

July 30, 2026

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

July 24, 2026

Cannabinoids Fall Short Across Most Psychiatric Disorders

"[T]he routine use of cannabinoids for the treatment of mental disorders and SUDs is rarely justified."

MDSpire News

July 23, 2026

New Data for Acquired Hypothalamic Obesity

Researchers found greater reductions in body mass index and participant-reported hunger scores with setmelanotide than with placebo, although adverse and serious adverse events were more frequent in the setmelanotide group; only one serious adverse event was considered treatment-related.

MDSpire News